Nucor earnings beat by $0.08, revenue fell short of estimates
CervoMed Inc. (NASDAQ:CRVO), a pharmaceutical company with a market capitalization of $85 million, announced executive transitions in a recent SEC filing. According to InvestingPro data, the company maintains strong liquidity with a current ratio of 11.11, indicating robust short-term financial stability despite challenging market conditions. Kelly Blackburn, previously Senior Vice President, has been appointed as Executive Vice President, Clinical Development, effective April 16, 2025. Blackburn’s new role comes with an annual base salary of $448,360 and a target annual bonus of 35% of her base salary.
Mark De Rosch, Ph.D., FRAPS, has been appointed Executive Vice President, Regulatory and Government Affairs and Program Management, effective May 1, 2025. Dr. De Rosch, who joined CervoMed in November 2024, will receive an annual base salary of $465,000 and a target annual bonus of 35%.
Both Blackburn and De Rosch have entered into employment agreements with CervoMed that include severance and change of control provisions, non-competition and non-solicitation clauses, and confidentiality obligations.
On April 14, 2025, the Board also approved a Separation Agreement with Robert J. Cobuzzi, Jr., Ph.D., the company’s Chief Operating Officer, who will depart effective July 1, 2025. Cobuzzi will receive a lump-sum payment equivalent to twelve months’ gross base salary, a pro-rated target annual bonus for 2025, and COBRA continuation coverage for 12 months. His stock options will continue to vest through September 30, 2026.
The press release did not include the reasons for the executive changes but provided details on the financial and contractual aspects of the appointments and separation agreement. The information in this article is based on the SEC filing by CervoMed Inc.
In other recent news, CervoMed has been the focus of multiple analyst upgrades following promising developments in its clinical trials. Jones Trading upgraded CervoMed from Hold to Buy, setting a new price target of $15.00, after positive results from an open-label extension study for neflamapimod, a treatment for dementia with Lewy bodies (DLB). Similarly, Chardan Capital Markets upgraded the stock to Buy with a price target of $14.00, citing improved drug efficacy in the 16-week phase of the RewinD-LB study. Brookline Capital Markets also raised CervoMed to Buy, with a $16.00 target, based on favorable interim data suggesting neflamapimod’s potential as a significant treatment advancement. Boral (OTC:BOALY) Capital joined in upgrading the stock to Buy, setting a $10.00 target, after discussing trial outcomes and future plans with CervoMed’s management. The company recently reported preliminary findings from its Phase 2b RewinD-LB trial, noting challenges with drug bioavailability but expressing optimism about future results from a new drug batch. These developments have collectively bolstered analyst confidence in CervoMed’s potential in addressing DLB, a progressive neurological disorder. Investors are closely watching the upcoming data releases, which are expected to further clarify the drug’s effectiveness and influence future FDA discussions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.